Literature DB >> 35766680

The use of neutralizing monoclonal antibody in patients with COVID-19: a systematic review and meta-analysis.

Suzana Erico Tanni1, Diane Rezende Batista1, Hélio Arthur Bacha2, Alexandre Naime Barbosa3, Wanderley Marques Bernardo4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35766680      PMCID: PMC9575896          DOI: 10.1590/1806-9282.2022D686

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.712


× No keyword cloud information.
  15 in total

1.  RoB 2: a revised tool for assessing risk of bias in randomised trials.

Authors:  Jonathan A C Sterne; Jelena Savović; Matthew J Page; Roy G Elbers; Natalie S Blencowe; Isabelle Boutron; Christopher J Cates; Hung-Yuan Cheng; Mark S Corbett; Sandra M Eldridge; Jonathan R Emberson; Miguel A Hernán; Sally Hopewell; Asbjørn Hróbjartsson; Daniela R Junqueira; Peter Jüni; Jamie J Kirkham; Toby Lasserson; Tianjing Li; Alexandra McAleenan; Barnaby C Reeves; Sasha Shepperd; Ian Shrier; Lesley A Stewart; Kate Tilling; Ian R White; Penny F Whiting; Julian P T Higgins
Journal:  BMJ       Date:  2019-08-28

2.  Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments.

Authors:  Luke A McGuinness; Julian P T Higgins
Journal:  Res Synth Methods       Date:  2020-04-26       Impact factor: 5.273

3.  REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.

Authors:  Alina Baum; Dharani Ajithdoss; Richard Copin; Anbo Zhou; Kathryn Lanza; Nicole Negron; Min Ni; Yi Wei; Kusha Mohammadi; Bret Musser; Gurinder S Atwal; Adelekan Oyejide; Yenny Goez-Gazi; John Dutton; Elizabeth Clemmons; Hilary M Staples; Carmen Bartley; Benjamin Klaffke; Kendra Alfson; Michal Gazi; Olga Gonzalez; Edward Dick; Ricardo Carrion; Laurent Pessaint; Maciel Porto; Anthony Cook; Renita Brown; Vaneesha Ali; Jack Greenhouse; Tammy Taylor; Hanne Andersen; Mark G Lewis; Neil Stahl; Andrew J Murphy; George D Yancopoulos; Christos A Kyratsous
Journal:  Science       Date:  2020-10-09       Impact factor: 47.728

4.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.

Authors:  Matthew J Page; Joanne E McKenzie; Patrick M Bossuyt; Isabelle Boutron; Tammy C Hoffmann; Cynthia D Mulrow; Larissa Shamseer; Jennifer M Tetzlaff; Elie A Akl; Sue E Brennan; Roger Chou; Julie Glanville; Jeremy M Grimshaw; Asbjørn Hróbjartsson; Manoj M Lalu; Tianjing Li; Elizabeth W Loder; Evan Mayo-Wilson; Steve McDonald; Luke A McGuinness; Lesley A Stewart; James Thomas; Andrea C Tricco; Vivian A Welch; Penny Whiting; David Moher
Journal:  BMJ       Date:  2021-03-29

Review 5.  Tackling COVID-19 with neutralizing monoclonal antibodies.

Authors:  Davide Corti; Lisa A Purcell; Gyorgy Snell; David Veesler
Journal:  Cell       Date:  2021-05-26       Impact factor: 41.582

6.  Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Authors: 
Journal:  Lancet       Date:  2022-02-12       Impact factor: 79.321

7.  Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

Authors:  Robert L Gottlieb; Ajay Nirula; Peter Chen; Joseph Boscia; Barry Heller; Jason Morris; Gregory Huhn; Jose Cardona; Bharat Mocherla; Valentina Stosor; Imad Shawa; Princy Kumar; Andrew C Adams; Jacob Van Naarden; Kenneth L Custer; Michael Durante; Gerard Oakley; Andrew E Schade; Timothy R Holzer; Philip J Ebert; Richard E Higgs; Nicole L Kallewaard; Janelle Sabo; Dipak R Patel; Paul Klekotka; Lei Shen; Daniel M Skovronsky
Journal:  JAMA       Date:  2021-02-16       Impact factor: 56.272

8.  Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.

Authors:  Meagan P O'Brien; Eduardo Forleo-Neto; Bret J Musser; Flonza Isa; Kuo-Chen Chan; Neena Sarkar; Katharine J Bar; Ruanne V Barnabas; Dan H Barouch; Myron S Cohen; Christopher B Hurt; Dale R Burwen; Mary A Marovich; Peijie Hou; Ingeborg Heirman; John D Davis; Kenneth C Turner; Divya Ramesh; Adnan Mahmood; Andrea T Hooper; Jennifer D Hamilton; Yunji Kim; Lisa A Purcell; Alina Baum; Christos A Kyratsous; James Krainson; Richard Perez-Perez; Rizwana Mohseni; Bari Kowal; A Thomas DiCioccio; Neil Stahl; Leah Lipsich; Ned Braunstein; Gary Herman; George D Yancopoulos; David M Weinreich
Journal:  N Engl J Med       Date:  2021-08-04       Impact factor: 91.245

9.  Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.

Authors:  Michael Dougan; Ajay Nirula; Masoud Azizad; Bharat Mocherla; Robert L Gottlieb; Peter Chen; Corey Hebert; Russell Perry; Joseph Boscia; Barry Heller; Jason Morris; Chad Crystal; Awawu Igbinadolor; Gregory Huhn; Jose Cardona; Imad Shawa; Princy Kumar; Andrew C Adams; Jacob Van Naarden; Kenneth L Custer; Michael Durante; Gerard Oakley; Andrew E Schade; Timothy R Holzer; Philip J Ebert; Richard E Higgs; Nicole L Kallewaard; Janelle Sabo; Dipak R Patel; Matan C Dabora; Paul Klekotka; Lei Shen; Daniel M Skovronsky
Journal:  N Engl J Med       Date:  2021-07-14       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.